Cargando…

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

INTRODUCTION: Hepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Regorafenib (Rego) or Cabozantinib in second-line. A major hindrance of TKI therapies is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Breitenecker, Kristina, Hedrich, Viola, Pupp, Franziska, Chen, Doris, Řezníčková, Eva, Ortmayr, Gregor, Huber, Heidemarie, Weber, Gerhard, Balcar, Lorenz, Pinter, Matthias, Mikulits, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514905/
https://www.ncbi.nlm.nih.gov/pubmed/37746265
http://dx.doi.org/10.3389/fonc.2023.1238883
_version_ 1785108827597701120
author Breitenecker, Kristina
Hedrich, Viola
Pupp, Franziska
Chen, Doris
Řezníčková, Eva
Ortmayr, Gregor
Huber, Heidemarie
Weber, Gerhard
Balcar, Lorenz
Pinter, Matthias
Mikulits, Wolfgang
author_facet Breitenecker, Kristina
Hedrich, Viola
Pupp, Franziska
Chen, Doris
Řezníčková, Eva
Ortmayr, Gregor
Huber, Heidemarie
Weber, Gerhard
Balcar, Lorenz
Pinter, Matthias
Mikulits, Wolfgang
author_sort Breitenecker, Kristina
collection PubMed
description INTRODUCTION: Hepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Regorafenib (Rego) or Cabozantinib in second-line. A major hindrance of TKI therapies is the development of resistance, which renders drug treatment futile and results in HCC progression. METHODS: In this study, we addressed the impact of the receptor tyrosine kinase Axl binding to its ligand Gas6 in acquiring refractoriness to TKIs. The initial responses of Axl-positive and Axl-negative cell lines to different TKIs were assessed. Upon inducing resistance, RNA-Seq, gain- and loss-of-function studies were applied to understand and intervene with the molecular basis of refractoriness. Secretome analysis was performed to identify potential biomarkers of resistance. RESULTS: We show that HCC cells exhibiting a mesenchymal-like phenotype were less sensitive to drug treatment, linking TKI resistance to changes in epithelial plasticity. Gas6/Axl expression and activation were upregulated in Rego-resistant HCC cells together with the induction of ErbB receptors, whereas HCC cells lacking Axl failed to stimulate ErbBs. Treatment of Rego-insensitive HCC cells with the pan-ErbB family inhibitor Afatinib rather than with Erlotinib blocking ErbB1 reduced cell viability and clonogenicity. Genetic intervention with ErbB2-4 but not ErbB1 confirmed their crucial involvement in refractoriness to Rego. Furthermore, Rego-resistant HCC cells secreted basic fibroblast growth factor (bFGF) depending on Axl expression. HCC patients treated with Sora in first-line and with Rego in second-line displayed elevated serum levels of bFGF, emphasizing bFGF as a predictive biomarker of TKI treatment. DISCUSSION: Together, these data suggest that the inhibition of ErbBs is synthetic lethal with Rego in Axl-expressing HCC cells, showing a novel vulnerability of HCC.
format Online
Article
Text
id pubmed-10514905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105149052023-09-23 Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma Breitenecker, Kristina Hedrich, Viola Pupp, Franziska Chen, Doris Řezníčková, Eva Ortmayr, Gregor Huber, Heidemarie Weber, Gerhard Balcar, Lorenz Pinter, Matthias Mikulits, Wolfgang Front Oncol Oncology INTRODUCTION: Hepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Regorafenib (Rego) or Cabozantinib in second-line. A major hindrance of TKI therapies is the development of resistance, which renders drug treatment futile and results in HCC progression. METHODS: In this study, we addressed the impact of the receptor tyrosine kinase Axl binding to its ligand Gas6 in acquiring refractoriness to TKIs. The initial responses of Axl-positive and Axl-negative cell lines to different TKIs were assessed. Upon inducing resistance, RNA-Seq, gain- and loss-of-function studies were applied to understand and intervene with the molecular basis of refractoriness. Secretome analysis was performed to identify potential biomarkers of resistance. RESULTS: We show that HCC cells exhibiting a mesenchymal-like phenotype were less sensitive to drug treatment, linking TKI resistance to changes in epithelial plasticity. Gas6/Axl expression and activation were upregulated in Rego-resistant HCC cells together with the induction of ErbB receptors, whereas HCC cells lacking Axl failed to stimulate ErbBs. Treatment of Rego-insensitive HCC cells with the pan-ErbB family inhibitor Afatinib rather than with Erlotinib blocking ErbB1 reduced cell viability and clonogenicity. Genetic intervention with ErbB2-4 but not ErbB1 confirmed their crucial involvement in refractoriness to Rego. Furthermore, Rego-resistant HCC cells secreted basic fibroblast growth factor (bFGF) depending on Axl expression. HCC patients treated with Sora in first-line and with Rego in second-line displayed elevated serum levels of bFGF, emphasizing bFGF as a predictive biomarker of TKI treatment. DISCUSSION: Together, these data suggest that the inhibition of ErbBs is synthetic lethal with Rego in Axl-expressing HCC cells, showing a novel vulnerability of HCC. Frontiers Media S.A. 2023-09-08 /pmc/articles/PMC10514905/ /pubmed/37746265 http://dx.doi.org/10.3389/fonc.2023.1238883 Text en Copyright © 2023 Breitenecker, Hedrich, Pupp, Chen, Řezníčková, Ortmayr, Huber, Weber, Balcar, Pinter and Mikulits https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Breitenecker, Kristina
Hedrich, Viola
Pupp, Franziska
Chen, Doris
Řezníčková, Eva
Ortmayr, Gregor
Huber, Heidemarie
Weber, Gerhard
Balcar, Lorenz
Pinter, Matthias
Mikulits, Wolfgang
Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
title Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
title_full Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
title_fullStr Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
title_full_unstemmed Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
title_short Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
title_sort synergism of the receptor tyrosine kinase axl with erbb receptors mediates resistance to regorafenib in hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514905/
https://www.ncbi.nlm.nih.gov/pubmed/37746265
http://dx.doi.org/10.3389/fonc.2023.1238883
work_keys_str_mv AT breiteneckerkristina synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT hedrichviola synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT puppfranziska synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT chendoris synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT reznickovaeva synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT ortmayrgregor synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT huberheidemarie synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT webergerhard synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT balcarlorenz synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT pintermatthias synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma
AT mikulitswolfgang synergismofthereceptortyrosinekinaseaxlwitherbbreceptorsmediatesresistancetoregorafenibinhepatocellularcarcinoma